title: [Long-term anti-cancer implants inhibiting the activity of tumor growth in animal models].
abstract: This study was aimed to establish rat bladder tumor animal models to investigate the in viva antitumor effect of polyanhydride-pirarubicin (PAD-THP), a long-lasting anti-cancer implant, in the bladder tumor of animal models. The model of bladder cancer was set up with N-butly-N-(4 hydroxybutyl) nitrosamine (BBN) feeding into rats. The PAD-THP long-acting anti-cancer implants containing the drugs and the same dose of the THP naked drug were placed under the bladder mucosa of bladder tumor model in vivo. The pirarubicin plasma concentration was measured with high performance liquid chromatography (HPLC) detection in vivo. The effective drug concentration and lasting period were observed and compared in the animal bodies. The tumor sizes were measured before and after the treatment. The in viva antitumor effects were analyzed and compared. The results showed that more significant antitumor effect of PAD-THP implants on the local drug release characteristics were presented compared with that of the same dose of THP bare drug group and there were significant differences (P<0. 05) between the two methods. All the results indicated that the PAD-THP anti-cancer implants in the postoperative local treatment of bladder tumors would show prosperous in the future for clinical application.
authors.affiliation: Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cells Tianjin 300170, China.
authors.forename: Meili
authors.initials: M
authors.lastname: Yu
authors.forename: Zhi
authors.initials: Z
authors.lastname: Du
authors.forename: Junchen
authors.initials: J
authors.lastname: Xue
authors.forename: Hongyue
authors.initials: H
authors.lastname: Guo
authors.forename: Ruoxi
authors.initials: R
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Xiong
authors.forename: Chan
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002085:Butylhydroxybutylnitrosamine; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D020007:Implants, Experimental; D049388:Polyanhydrides / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D049388:Polyanhydrides; D002085:Butylhydroxybutylnitrosamine; D004317:Doxorubicin; C027260:pirarubicin